Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

Chouaïd, C.; Agulnik, J.; Göker, Erdem; Herder, Gerarda J.M.; Lester, J.F.; Vansteenkiste, Johann; Finnern, Henrik W.; Lungershausen, Juliane; Eriksson, Jennifer; Kim, Kun; Mitchell, Paul

doi:10.1097/jto.0b013e318299243b

Cited by 116 publications

(122 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In accordance with the findings from this survey, high rates of anxiety/depression have been reported in patients with advanced nonsmall cell lung cancer [23], rheumatoid arthritis [24,25] and severe asthma [26]. Moreover, a negative impact of chronic disease on patients' mental function [24,27], role, emotional or social functioning [24,28,29], and both the intensity and quality of sexual relationships [30] has been described.…”

Section: Implications For the Future Management Of Pahsupporting

confidence: 69%

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Guillevin¹,

Armstrong²,

Aldrighetti³

et al. 2013

European Respiratory Review

129

214

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease. Although there have been important medical advances in PAH management, the search for a cure continues. Despite an increased understanding of the disease, data on the wider effect of PAH on patients and carers, beyond the clinical symptoms, are still limited. In order to explore this, a large-scale international survey investigated four key areas affected by PAH (physical and practical, emotional, social, and information needs) and provides new insight into patients' and carers' experiences of living with the disease. The results from the survey highlight not only the limited ability of patients to carry out everyday tasks, but also the financial impact and social isolation experienced by both patients and carers. The study confirmed that a decline in a patient's World Health Organization functional class, which indicates an increase in clinical severity of the disease, is associated with greater limitations. Results from the survey demonstrate the need for multidisciplinary PAH management and a comprehensive standard of care to assess and improve all aspects of well-being for both patients and carers. In addition, they underline the need for updated PAH guidelines that address these needs. @ERSpublications PAH has a profound impact on numerous aspects of patients' and carers' lives http://ow.ly/pWWYf This article has supplementary material available from err.ersjournals.comFull survey results, along with a call to action, are available at www.phaeurope.org/projects-activities/pah-patient-andcarer-survey

show abstract

Section: Implications For the Future Management Of Pahsupporting

confidence: 69%

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Guillevin¹,

Armstrong²,

Aldrighetti³

et al. 2013

European Respiratory Review

129

214

View full text Add to dashboard Cite

show abstract

“…Lung cancer patients, particularly those in an advanced stage, suffer from poor physical condition, which often negatively affects their quality of life 13. A recent study conducted on non-small-cell lung cancer (NSCLC) patients suggested that lung cancer with stage IV disease, higher line of treatment, and more progressive disease substantially impacted patient quality of life 20. Poor quality of life may cause various psychiatric disorders, including depression.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and relationship between major depressive disorder and lung cancer: a cross-sectional study

Maneeton

Reungyos

et al. 2014

OTT

View full text Add to dashboard Cite

ObjectiveThe aims of this study were to estimate the prevalence and examine the factors associated with major depressive disorder (MDD) in lung cancer patients.Materials and methodsThis cross-sectional study was carried out in the oncology clinic of the University Hospital, Chiang Mai University, Thailand. Patients with all stages of lung cancer were included in this study. Demographic data of eligible patients were gathered. The Mini-International Neuropsychiatric Interview, Thai version 5.0.0 was used to identify MDD. The Thai version of the Personal Health Questionnaire Depression Scale was used to assess depression severity.ResultsA total of 146 lung cancer patients from the outpatient clinic from July to December 2012 were approached. The 104 patients were included and analyzed in this study. Based on the Mini-International Neuropsychiatric Interview, 14.4% of them were defined as having MDD. Multiple linear regression analysis revealed that Chalder Fatigue Scale, Functional Assessment of Cancer Therapy – Lung, and Pittsburgh Sleep Quality Index scores were significantly correlated with MDD in lung cancer patients.ConclusionThe results suggest that MDD is more prevalent in lung cancer patients. In addition, fatigue, poor quality of life, and sleep disturbance may increase associated MDD. Because of the small sample size, further studies should be conducted to confirm these results.

show abstract

“…The utility scores of PFS and survival after progression were obtained from previously published studies (Table 2) [44, 45]. The reported disutility caused by SAEs was also considered in the current analysis [44].…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Lü

Ding

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR mutation, but the economic impact of this practice is unclear, especially in a health resource-limited setting. A decision-analytic model was developed to simulate 21-day patient transitions in a 10-year time horizon. The health and economic outcomes of four first-line strategies (pemetrexed plus cisplatin [PC] alone, PC followed by maintenance with pemetrexed, or initial treatment with gefitinib or icotinib) among patients harboring EGFR mutations were estimated and assessed via indirect comparisons. Costs in the Chinese setting were estimated. The primary outcome was the incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed. The icotinib strategy resulted in greater health benefits than the other three strategies in NSCLC patients harboring EGFR mutations. Relative to PC alone, PC followed by pemetrexed maintenance, gefitinib and icotinib resulted in ICERs of $104,657, $28,485 and $19,809 per quality-adjusted life-year gained, respectively. The cost of pemetrexed, the EGFR mutation prevalence and the utility of progression-free survival were factors that had a considerable impact on the model outcomes. When the icotinib Patient Assistance Program was available, the economic outcome of icotinib was more favorable. These results indicate that gene-guided therapy with icotinib might be a more cost-effective treatment option than traditional chemotherapy.

show abstract

Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

Abstract: The results presented indicate a substantial impact of lung cancer on patients' HRQOL, with stage IV disease, line of treatment, and PD, resulting in considerable deterioration of utility. The values obtained here will inform evaluations of cost-utility for NSCLC therapies.

Cited by 116 publications

References 19 publications

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Prevalence and relationship between major depressive disorder and lung cancer: a cross-sectional study

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Contact Info

Product

Resources

About